Candel Therapeutics, Inc. (CADL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 93 |
| Operating profit | $m | -48 | -72 | ||||||
| Net profit | $m | -18 | -36 | -19 | -38 | -55 | -38 | -89 | -65 |
| EPS reported | $ | -0.72 | -1.41 | ||||||
| Operating cashflow per share | $ | -0.72 | -0.76 | ||||||
| Capex per share | $ | 0.01 | 0.02 | ||||||
| FCF per share | $ | -0.73 | -0.77 | ||||||
| Free cash flow | $m | -39 | -57 | ||||||
| Net debt | $m | -118 | -154 | ||||||
| Book value equity | $m | 52 | 126 | ||||||
| Book value per share | $ | 0.98 | 1.70 | ||||||
| Number of shares | m | 52.96 | 74.13 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 5.76 | 2.37 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -7.69 | -5.22 | ||||||
| EV/EBITDA LTM | x | -5.15 | -2.19 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -12.76% | -9.34% | ||||||
| FCF Yield | % | -13.00% | -19.16% | ||||||
| Quality | |||||||||
| ROE | % | -73.54% | -89.38% | ||||||
| ROIC | % | -41.38% | -36.74% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -20.43 | -1.16 | ||||||
| Net Debt/EBITDA | x | 3.35 | 1.83 | ||||||
| EBIT/Net interest | x | -22.78 | -15.26 | ||||||
| Net debt/market cap | % | +0.64% | +5.11% | ||||||
| Net debt/Equity | x | -2.27 | -1.22 | ||||||
| Gross debt/equity | x | 0.04 | 0.39 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Candel Therapeutics, Inc. (CADL)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free